Skip to main content
Erschienen in: European Radiology 3/2018

10.10.2017 | Oncology

Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now

verfasst von: Massimo Galia, Domenico Albano, Corrado Tarella, Caterina Patti, Luca Maria Sconfienza, Antonino Mulè, Pierpaolo Alongi, Massimo Midiri, Roberto Lagalla

Erschienen in: European Radiology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The indolent non-Hodgkin lymphomas (i-NHLs) are characterised by ‘indolent’ clinical behaviour with slow growth and prolonged natural history. The watchful waiting (WW) strategy is a frequently employed treatment option in these patients. This implies a strict monitoring by imaging examinations, including 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) and CT. A major concern is radiation exposure due to regularly monitoring by conventional imaging procedures. Several studies have demonstrated the reliability of whole-body magnetic resonance imaging (WB-MRI) for lymphoma staging. WB-MRI could be useful for active surveillance in i-NHLs providing the suspect of disease progression that can be then confirmed by additional diagnostic procedures, including 18F-FDG-PET/CT. The directive 2013/59 by the European Union claims that if a radiation-free imaging technique allows obtaining the same diagnostic results, it should be invariably used. In this setting, WB-MRI may be considered a reasonable option in i-NHLs under WW, replacing imaging modalities that cause exposure to ionising radiations. This will help to reduce the cancer risk in i-NHL patients for whom chemo-/radiotherapy remain the usual treatment options following the usually long WW phase. The scientific community should raise the awareness of the risk of ionising radiations in i-NHLs and the emphasise the need for establishing the proper place of WB-MRI in lymphoma imaging.

Key Points

Watchful waiting is a reasonable option in patients with indolent non-Hodgkin lymphomas.
Imaging is crucial to monitor patients with indolent non-Hodgkin lymphomas.
CT and 18 F-FDG-PET/CT are commonly used, implying a substantial radiation exposure.
WB-MRI is highly reliable in lymphoma staging.
WB-MRI may be considered to monitor indolent non-Hodgkin lymphomas under watchful waiting.
Literatur
2.
Zurück zum Zitat Armitage JO, Longo DL (2016) Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood 127:2804–2808CrossRefPubMed Armitage JO, Longo DL (2016) Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood 127:2804–2808CrossRefPubMed
3.
Zurück zum Zitat Sorigue M, Sancho JM, Ribera JM (2016) Open questions in watchful waiting for follicular lymphoma. Br J Haematol (in press) Sorigue M, Sancho JM, Ribera JM (2016) Open questions in watchful waiting for follicular lymphoma. Br J Haematol (in press)
4.
Zurück zum Zitat Zinzani PL, Marchetti M, Billio A et al (2013) Expert Panel of the Italian Society of Hematology. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 88:185–192CrossRefPubMed Zinzani PL, Marchetti M, Billio A et al (2013) Expert Panel of the Italian Society of Hematology. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 88:185–192CrossRefPubMed
5.
Zurück zum Zitat Tarella C, Arcaini L, Baldini L et al (2015) Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk 15:75–85CrossRefPubMed Tarella C, Arcaini L, Baldini L et al (2015) Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk 15:75–85CrossRefPubMed
6.
Zurück zum Zitat Arcaini L, Lazzarino M, Colombo N et al (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107:4643–4649CrossRefPubMed Arcaini L, Lazzarino M, Colombo N et al (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107:4643–4649CrossRefPubMed
7.
Zurück zum Zitat Matutes E, Oscier D, Montalban C et al (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487–495CrossRefPubMed Matutes E, Oscier D, Montalban C et al (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487–495CrossRefPubMed
8.
Zurück zum Zitat Raderer M, Kiesewetter B, Ferreri AJ (2016) Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 66:153–171CrossRefPubMed Raderer M, Kiesewetter B, Ferreri AJ (2016) Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 66:153–171CrossRefPubMed
9.
Zurück zum Zitat Tanimoto K, Kaneko A, Suzuki S et al (2006) Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135–140CrossRefPubMed Tanimoto K, Kaneko A, Suzuki S et al (2006) Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135–140CrossRefPubMed
10.
Zurück zum Zitat Troch M, Streubel B, Petkov V, Turetschek K, Chott A, Raderer M (2007) Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 27:3633–3637PubMed Troch M, Streubel B, Petkov V, Turetschek K, Chott A, Raderer M (2007) Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 27:3633–3637PubMed
11.
Zurück zum Zitat Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522CrossRefPubMed Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522CrossRefPubMed
12.
Zurück zum Zitat Tadmor T, Polliack A (2012) Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. Blood Rev 26:15–23CrossRefPubMed Tadmor T, Polliack A (2012) Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. Blood Rev 26:15–23CrossRefPubMed
13.
Zurück zum Zitat Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209–1213CrossRefPubMed Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209–1213CrossRefPubMed
14.
Zurück zum Zitat Dreyling M, Ferrero S, Hermine O (2014) How to manage mantle cell lymphoma. Leukemia 28:2117–2130CrossRefPubMed Dreyling M, Ferrero S, Hermine O (2014) How to manage mantle cell lymphoma. Leukemia 28:2117–2130CrossRefPubMed
15.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 32:3059–3067CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 32:3059–3067CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood 128:2489–2496CrossRefPubMed Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood 128:2489–2496CrossRefPubMed
17.
Zurück zum Zitat Brenner DJ, Hall EJ (2007) Computed tomography: an increasing source of radiation exposure. N Engl J Med 357:2277–2284CrossRefPubMed Brenner DJ, Hall EJ (2007) Computed tomography: an increasing source of radiation exposure. N Engl J Med 357:2277–2284CrossRefPubMed
18.
Zurück zum Zitat Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR (2010) Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin. Lymphoma Myeloma Leuk 10:270–277CrossRef Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR (2010) Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin. Lymphoma Myeloma Leuk 10:270–277CrossRef
19.
Zurück zum Zitat Chien SH, Liu CJ, Hu YW et al (2015) Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study. Int J Cancer 137:658–665CrossRefPubMed Chien SH, Liu CJ, Hu YW et al (2015) Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study. Int J Cancer 137:658–665CrossRefPubMed
20.
Zurück zum Zitat Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation ofradiation dose and cancer risk. Radiology 251:166–174CrossRefPubMed Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation ofradiation dose and cancer risk. Radiology 251:166–174CrossRefPubMed
21.
Zurück zum Zitat Luminari S, Biasoli I, Arcaini L et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24:2108–2112CrossRefPubMed Luminari S, Biasoli I, Arcaini L et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24:2108–2112CrossRefPubMed
24.
Zurück zum Zitat Albano D, Patti C, La Grutta L et al (2016) Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 85:313–318CrossRefPubMed Albano D, Patti C, La Grutta L et al (2016) Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 85:313–318CrossRefPubMed
25.
Zurück zum Zitat Mayerhoefer ME, Karanikas G, Kletter K et al (2015) Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET/CT–controlled prospective study in 64 patients. Clin Cancer Res 21:2506–2513CrossRefPubMed Mayerhoefer ME, Karanikas G, Kletter K et al (2015) Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET/CT–controlled prospective study in 64 patients. Clin Cancer Res 21:2506–2513CrossRefPubMed
26.
Zurück zum Zitat Lin C, Luciani A, Itti E et al (2010) Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 20:2027–2038CrossRefPubMed Lin C, Luciani A, Itti E et al (2010) Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 20:2027–2038CrossRefPubMed
27.
Zurück zum Zitat Littooij AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 24:1153–1165CrossRefPubMed Littooij AS, Kwee TC, Barber I et al (2014) Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol 24:1153–1165CrossRefPubMed
28.
Zurück zum Zitat Albano D, La Grutta L, Grassedonio E et al (2016) Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: what radiologists should know. Magn Reson Imaging 34:922–931CrossRefPubMed Albano D, La Grutta L, Grassedonio E et al (2016) Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: what radiologists should know. Magn Reson Imaging 34:922–931CrossRefPubMed
29.
Zurück zum Zitat King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: Diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245:806–813CrossRefPubMed King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: Diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245:806–813CrossRefPubMed
30.
Zurück zum Zitat Kwee TC, Vermoolen MA, Akkerman EA et al (2013) Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study. J Magn Reson Imaging 40:26–36CrossRefPubMed Kwee TC, Vermoolen MA, Akkerman EA et al (2013) Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study. J Magn Reson Imaging 40:26–36CrossRefPubMed
31.
Zurück zum Zitat Balbo-Mussetto A, Cirillo S, Bruna R et al (2016) Whole-body MRI with diffusion-weighted imaging: A valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Clinical Radiology 71:271–279CrossRefPubMed Balbo-Mussetto A, Cirillo S, Bruna R et al (2016) Whole-body MRI with diffusion-weighted imaging: A valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Clinical Radiology 71:271–279CrossRefPubMed
32.
Zurück zum Zitat Adams HJ, Kwee TC, Vermoolen MA et al (2013) Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol 23:2271–2278CrossRefPubMed Adams HJ, Kwee TC, Vermoolen MA et al (2013) Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol 23:2271–2278CrossRefPubMed
33.
Zurück zum Zitat Albano D, Patti C, Lagalla R, Midiri M, Galia M (2017) Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 45:1082–1089CrossRefPubMed Albano D, Patti C, Lagalla R, Midiri M, Galia M (2017) Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 45:1082–1089CrossRefPubMed
34.
Zurück zum Zitat Iannitto E, Tripodo C (2011) How I diagnose and treat splenic lymphomas. Blood 117:2585–2595CrossRefPubMed Iannitto E, Tripodo C (2011) How I diagnose and treat splenic lymphomas. Blood 117:2585–2595CrossRefPubMed
35.
Zurück zum Zitat Vose JM (2015) Mantle cell lymphoma: 2015 update on diagnosis, risk stratification, and clinical management. Am J Hematol 90:739–745CrossRefPubMed Vose JM (2015) Mantle cell lymphoma: 2015 update on diagnosis, risk stratification, and clinical management. Am J Hematol 90:739–745CrossRefPubMed
37.
Zurück zum Zitat Albano D, Patti C, La Grutta L et al (2017) Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin lymphoma treated by BEACOPP. Eur Radiol 27:2129–2136CrossRefPubMed Albano D, Patti C, La Grutta L et al (2017) Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin lymphoma treated by BEACOPP. Eur Radiol 27:2129–2136CrossRefPubMed
38.
Zurück zum Zitat Littooij AS, Kwee TC, Goya E et al (2017) Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma. Br J Haematol 176:637–642CrossRefPubMed Littooij AS, Kwee TC, Goya E et al (2017) Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma. Br J Haematol 176:637–642CrossRefPubMed
39.
Zurück zum Zitat Albano D, Patti C, Sconfienza LM, Galia M (2017) Whole-body MRI in the early detection of multifocal osteonecrosis. Br J Radiol 190:20170240CrossRef Albano D, Patti C, Sconfienza LM, Galia M (2017) Whole-body MRI in the early detection of multifocal osteonecrosis. Br J Radiol 190:20170240CrossRef
40.
Zurück zum Zitat Messina C, Banfi G, Aliprandi A et al (2016) Ultrasound guidance to perform intra-articular injection of gadolinium-based contrast material for magnetic resonance arthrography as an alternative to fluoroscopy: the time is now. Eur Radiol 26:1221–1225CrossRefPubMed Messina C, Banfi G, Aliprandi A et al (2016) Ultrasound guidance to perform intra-articular injection of gadolinium-based contrast material for magnetic resonance arthrography as an alternative to fluoroscopy: the time is now. Eur Radiol 26:1221–1225CrossRefPubMed
41.
Zurück zum Zitat Wu X, Sikiö M, Pertovaara H et al (2016) Differentiation of diffuse large B-cell lymphoma from follicular lymphoma using texture analysis on conventional MR images at 3.0 Tesla. Acad Radiol 23:696–703CrossRefPubMed Wu X, Sikiö M, Pertovaara H et al (2016) Differentiation of diffuse large B-cell lymphoma from follicular lymphoma using texture analysis on conventional MR images at 3.0 Tesla. Acad Radiol 23:696–703CrossRefPubMed
Metadaten
Titel
Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now
verfasst von
Massimo Galia
Domenico Albano
Corrado Tarella
Caterina Patti
Luca Maria Sconfienza
Antonino Mulè
Pierpaolo Alongi
Massimo Midiri
Roberto Lagalla
Publikationsdatum
10.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 3/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5071-x

Weitere Artikel der Ausgabe 3/2018

European Radiology 3/2018 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.